Exagen Inc. (XGN) Stock

Exagen Inc., formerly known as Exagen Diagnostics, Inc., specializes in the development and commercialization of advanced testing products leveraging its proprietary cell-bound complement activation products technology. Operating under the AVISE brand in the United States, Exagen empowers rheumatologists in the comprehensive management of autoimmune and autoimmune-related diseases. These conditions include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and various connective tissue diseases (CTDs), which can present overlapping symptoms challenging to diagnose accurately.

At the forefront of Exagen's offerings is the AVISE CTD test, designed to facilitate differential diagnosis among patients exhibiting symptoms indicative of CTDs and related diseases. The company also provides specialized tests such as AVISE Lupus, which measures complement system activation, and AVISE APS, a panel aiding in the diagnosis and management of antiphospholipid syndrome (APS). Additionally, Exagen offers AVISE SLE Prognostic for assessing complications in vital organs and AVISE Vasculitis AAV for monitoring anti-neutrophil cytoplasmic antibody-associated vasculitis.

Innovation drives Exagen's commitment to advancing patient care and clinical outcomes. Beyond diagnostic tools, Exagen collaborates with institutions like Allegheny Health Network Research Institute to develop novel biomarkers. Founded in 2002 and headquartered in Vista, California, Exagen Inc. continues to lead in delivering reliable diagnostic solutions tailored to meet the evolving needs of rheumatology practices nationwide.